101 results about "Treatment choices" patented technology

A method and system for orthodontic treatment planning, evaluation and quality measurement is provided comprising a workstation having computing platform, a graphical user interface, a processor and a computer storage medium containing digitized records pertaining to a patient. The digitized records include image and other types of data. The computer storage medium further includes a set of software instructions providing graphical user interface tools for providing a user with access to the digitized records for planning orthodontic treatment of a patient. Also provided are reference databases for aiding in the decision process during treatment selection, treatment planning and treatment delivery and progress monitoring and evaluation. Also provided are parameter or criteria measurement techniques and generally acceptable thresholds, which can be updated through learning process and through acquisition of patient data. Once the treatment is planned, the virtual dentition model of the patient in the proposed treatment set-up or the target state is evaluated using several virtual model evaluation features and criteria.

A medical digital expert system to predict a patient's response to a variety of treatments (using pre-treatment information) is described. The system utilizes data fusion, advanced signal / information processing and machine learning / inference methodologies and technologies to integrate and explore diverse sets of attributes, parameters and information that are available to select the optimal treatment choice for an individual or for a subset of individuals suffering from any illness or disease including psychiatric, mental or neurological disorders and illnesses. The methodology and system can also be used to determine or confirm medical diagnosis, estimate the level, index, severity or critical medical parameters of the illness or condition, or provide a list of likely diagnoses for an individual suffering / experiencing any illness, disorder or condition.

Different types of cardiac arrhythmia are classified based on the morphology of the arrhythmic beats. Cardiac beats associated with an arrhythmic episode are compared to a plurality of representative beat morphologies, each representative beat morphology characterizing a type of arrhythmia of the heart. An arrhythmic episode may be classified as a particular type of arrhythmia if the morphology of the arrhythmic cardiac beats matches a representative beat morphology characterizing the particular type of arrhythmia. An appropriate therapy for the particular type of arrhythmia may be selected based on the arrhythmia classification. A particular type of arrhythmia may be associated with one or more therapies used to treat the arrhythmia. The therapy used to treat the arrhythmia may comprise a therapy identified as a previously successful therapy.

A therapeutic pad system (200) is disclosed for the treatment of edema, wherein the pressure applied to the user by the pad encourages the proximal flow of lymph. A fluid is provided to one or more bladder-type pads (220) in the pad through an inlet port (218) at a distal end of the pad, and is expelled from the bladder through an outlet port (220) at the proximal end of the bladder, thereby producing a pressure gradient across the pad. The system includes a flexible and compressible liner (250) filled with a number of small foam pieces (258) that is adapted to be wrapped about the therapeutic pad, and a relatively rugged, outer binder (270) that is securable about the liner (250). An advantage of the present system is that it may be applied in a number of different modes and combinations providing many treatment options.

A system and method are provided for significantly reducing or substantially eliminating angular geometric distortions in devices designed for imaging and / or inspection of an interior portion or surface of a cavity. A series of processing steps or methods may be employed to eliminate Non-Uniform Rotational Distortion (NURD) in such devices, for example, unidirectional and bi-directional intravascular ultrasonic (IVUS) imaging systems. The system may include a processor and an electronic module which control operation of a transducer assembly provided at a distal end of a catheter assembly. The system invokes a first processing step or method to collect and store raw angle and line data, as well as one or more of second and third processing steps or methods which adjust for NURD experienced during backlash of a bi-directional imaging system and a fourth processing step or method which performs a line-to-line correlation function. The system and method provide more accurate and reliable angular orientations of anomalies identified during imaging and / or inspection of the interior portion or surface of the cavity, thus facilitating diagnosis and treatment options.

A method and apparatus are provided for addressing vascular stenotic lesions. The geometry of a stenotic lesion zone is determined and is used to determine pressure drop of blood flow across the lesion zone or a portion thereof. The pressure drop value is used to determine a treatment regimen for the stenotic lesion zone. The geometry if preferably a three dimensional geometry. The apparatus provides pressure drop values to a physician so the physician can treat the patient if treatment is needed and provides direction for treatment options as to type and degree.

A pain measurement and diagnostic system (PMD) for bioanalytical analysis of pain matrix activity and the autonomic nervous system to diagnose and validate patient treatments, health status and outcomes. The PMD is implemented using medical devices for measuring and reporting objective measurements of pain through patient monitoring and analyzing related biological, psychological, social, environmental, and demographic factors that may contribute to and effect physiological outcomes for patients and through the integrated and iterative analysis improve diagnosis of pain, the evaluation of related disease states, health status, and treatment options.

Systems and methods are described herein for disease knowledge modeling and clinical treatment decision support, and the prioritization of possible treatment options based on tumor or other disease biomarkers. Disease or indication information, including identification of biomolecular entities associated with the indication may be culled through text data mining to create a knowledge model of the indication. In some embodiments, the knowledge model may comprise a network of associations between molecular entities, including such drug targets and biomakers, genes, pathways. The model may be combined with patient-specific variant information and historical treatment records to identify and prioritize treatment decisions and allow for the prediction of disease drivers and provide treatment options tailored to a patient's genetic data.

A simplified insulin pump allows type II diabetics to identify routine patterns in their daily lifestyle that provide a generally accurate typical pattern of activity and meals. An infusion regimen can be programmed into the pump that generally correlates with this typical pattern to provide a viable treatment option for a type II diabetic without the need for specific and precise matching of insulin to carbohydrate consumption or activity level.

An apparatus, system, and method are disclosed for determining a patient's condition. A system for determining a patient's condition, in one embodiment, comprises a computer processor device, an interface between the computer processor and one or more patient monitoring devices, and a software program configured to interpret patient input data, diagnose the patient's condition, and recommend treatment options. A method for determining a patient's condition may comprise receiving patient data from one or more patient monitoring devices, consulting a treatment database, determining a diagnosis, and converting a diagnosis into a treatment.

A therapeutic pad system (200) is disclosed for the treatment of edema, wherein the pressure applied to the user by the pad encourages the proximal flow of lymph. A fluid is provided to one or more bladder-type pads (220) in the pad through an inlet port (218) at a distal end of the pad, and is expelled from the bladder through an outlet port (220) at the proximal end of the bladder, thereby producing a pressure gradient across the pad. The system includes a flexible and compressible liner (250) filled with a number of small foam pieces (258) that is adapted to be wrapped about the therapeutic pad, and a relatively rugged, outer binder (270) that is securable about the liner (250). An advantage of the present system is that it may be applied in a number of different modes and combinations providing many treatment options.

A system enables a healthcare organization to evaluate cost efficient treatment options early in a patient treatment process by automatic monitoring of profit or loss of a treatment, in real-time and enables a clinical user to screen, simulate and control treatment profit or loss during a patient visit, based on both expected reimbursement and the actual costs of performed services. A system enables cost based treatment selection by providing a healthcare worker with patient specific treatment cost information during a treatment episode. An acquisition processor automatically interrogates at least one information repository for data concerning cost to a healthcare organization of providing a proposed treatment to a patient and expected cost reimbursement to the healthcare organization for the proposed treatment. The acquisition processor initiates generation of at least one message including a patient identifier and treatment identification code for communication to the at least one information repository, in response to data indicating occurrence of a treatment related event. A display processor initiates generation of data representing at least one display image including information indicating the proposed treatment is unprofitable for the healthcare organization.

A tissue treatment selection device that has at least one treatment delivery member, a delivery setting circuit that is coupled to the treatment delivery member that is adapted to be deployed into tissue to deliver therapeutic energy to a target tissue zone, and the processing circuit is operable to set treatment parameters in the delivery setting circuit that is operable to set treatment parameters in the delivery setting circuit. The processing circuit is operable to transmit a test signal through the deployed treatment delivery member and to determine deployment status. The treatment selection device has a processing circuit adapted to send a message to a display device that indicates that the deployed treatment delivery member has been determined to be compensable and contains a suggested change in the treatment parameters. Also presented herein is a method of treating a tissue of a patient using the treatment delivery device.

While a pharmacist may know of other medications approved by the FDA for the same medical condition, the pharmacist typically does not know what the therapeutically equivalent dose of those products is when compared to the originally prescribed item In addition to this lack of equivalent dosage information, the pharmacist also is unable to determine if any of those other FDA approved items will save the consumer any money. Accordingly, embodiments of the invention can provide pharmacists and / or consumers with equivalent dosage information as well as pricing information for the equivalent dosage. Accordingly, based at least in part on this information, consumers may have an incentive to and may decide to purchase to another prescription drug, thereby shifting market share to a preferred prescription drug or pharmaceutical manufacturer or provider.

This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitors when administered to subjects.

A knowledgebase comprising a plurality of feature-sets is created using complexity science. The knowledgebase is accessible through a network to a computer, a system, and a computer program code that receives and analyzes medical data to determine the existence of a disease state. The medical data is input and correlated to features within the knowledgebase to identify feature-sets, each feature-set indicating a particular medical condition. After one or more feature-sets have been selected, associative algorithms consider the magnitudes or values of the medical data and, with the values of features in the feature-sets, assess the risk burden of the medical condition associated with the feature-set. An output is generated that may include diagnoses of one or more medical conditions, the risk burden of the medical condition(s), possible treatment options and prevention techniques.

Methods are presented in which release of stem cells from skeletal muscle is quantitated and correlated with severity of a disease or trauma, a future treatment option, prognosis, and / or anticipated time to recovery. Most preferably, the stem cell is a BLSC and / or an ELSC, and the stem cell isolation for the cell count is performed using sedimentation or filtration as principal separation step, thereby avoiding commonly used complicated, expensive, and time-consuming processes such as antibody-based separation and fluorescence-activated cell sorting.

A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T / T) for IL-8(−251); (ii) (T / T or C / T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats.

Current treatment options for Overactive Bladder and Urinary Incontinence include exercise and behavioral modifications, pharmacological therapies, surgical intervention, and neuromodulation. Although each of these treatments is used in the treatment of individuals with these conditions, each has severe limitations. Building on the limitations of existing therapies, and with the distillation of lessons learned from the field of pulsed electric stimulation, the present invention employs Low Frequency Induction Therapy for the delivery of an effective, cost efficient, noninvasive alternative to available treatment options. The device of the present application allows for consistent, user-friendly modulation of the pudendal nerve and the sacral plexus, via pulsed electromagnetic stimulation of the posterior tibial nerve, on an outpatient basis. The device has two primary components: a programmable Logic Controller (LC), which generates the required current, and a Conductive Wrap (CW), through which the current is channeled in generating the pulsed electromagnetic fields.

A method and apparatus of occluding a lumen of a body cavity, more preferably, the lower uterine segment and / or cervix of a female patient is provided that results in a significant reduction or complete elimination of uterine bleeding, thereby providing a treatment option for conditions such as menorrhagia or dysmenorrhea.

A system and method for coordinated evaluation and prescription of unregulated therapeutic substances in a supervised medical environment, wherein the unregulated therapeutic substances, derived from natural products, are initially qualified as a therapeutic option to traditional prescription and OTC medicines. The implementation of the system and method of qualification and prescription of unregulated therapeutic substances is performed within the context of a mainstream medical care environment comprising an established health care management system wherein patient subscribers, within a given system, elect to participate in a trial evaluation under the supervision of the medical professional responsible for their care. Upon successful completion of the evaluation, the patient is empowered, with his medical professional's approval, to adopt the unregulated therapeutic substances for treatment of his illness or condition, and the established health care management system is obligated to reimburse such patient for such unregulated therapeutic substances.

Methods are provided for preventing neurodegeneration and neuronal loss by administering compositions comprising small molecule compounds with the effect of preventing neurodegeneration and neuronal loss. In one aspect of the invention, the methods and compositions are also useful for treating neurodegenerative diseases. Small molecule compounds provide an important treatment option because of their stability, ease of use in both manufacture and formulation, ease of administration, and patient compliance. The small molecule compound compositions of the present invention may include topoisomerase II inhibitors, bacterial transpeptidase inhibitors, calcium channel antagonists, cyclooxygenase inhibitors, folic acid synthesis inhibitors, or sodium channel blockers and functional analogues thereof that have an effect on neurodegeneration. The compositions of the present invention may be administered prophylactically before the onset of clinical symptoms or after clinical symptoms of a neurodegenerative disease have manifested.

A non-invasive method of treating cerebral ischemia, involving the use of non-inhaled, intra-nasally delivered carbon dioxide (CO2), alone or in combination with other gases to augment cerebral perfusion and improve outcome following a stroke is provided. A vasodilator gas is delivered intranasally, alone or in combination with a second gas, for prolonged periods of time without systemic absorption. The second gas may be selected from NO, hydrogen, xenon, anesthetic gases, oxygen, nitrogen, nitrous oxide, carbon monoxide, or air. The treatment selectively increases cerebral perfusion and provides neuroprotection in the treatment of cerebral ischemia.

Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl Lex, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.

A method in which photodynamic therapy is employed to inhibit, stabilize or reduce occlusions within the cardiovascular system by utilizing light within the spectral region of approximately 390 to approximately 610 nm.

Consumer healthcare decisions are facilitated using systems, methods and computer program products configured to generate healthcare path recommendations based a consumer engagement with a consumer interface in which consumer-reported information related to a consumer health condition is received and used to generate healthcare path recommendations. The healthcare path recommendations are customized for the consumer based on the consumer's personalized information including the consumer's engagement with the consumer interface. The customized healthcare paths include treatment options for addressing the health of the consumer and may include cost-effective providers.

Systems and methods for calculating health care treatment statistics are provided. In one embodiment, a system comprises a data-holding subsystem storing raw medical claims data in non-transitory memory, and a logic subsystem configured to partition the raw medical claims data into a plurality of data sets based on one or more of insurance type, episode grouping, member key, date-of-service key, or a combination thereof, wherein the logic subsystem is further configured to calculate statistics based on each of the plurality of data sets and output correlated calculation results for display on a user device, and wherein the statistics include a frequency of patients receiving a health care service and an average cost of the health care service. In this way, a health care consumer may know what to expect for different treatment options for a given medical condition.

Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.